EUVIMEDEUVIMED entdecken
Crossref

Multiple myeloma management: What comes after lenalidomide-based therapy?

Martha Louzada

Canadian Hematology Today · 2022

DOI: 10.58931/cht.2022.1213 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Hematology Today, 2022. Verfasst von Martha Louzada. Die Arbeit nennt 20 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Over the past two decades a myriad of new combination strategies and therapeutic agents for the treatment of multiple myeloma (MM) have been developed. Novel drug classes such as proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies have demonstrated very promising efficacy outcomes related to survival endpoints and improvements in quality of life for myeloma patients.

Zitieren

APA

Louzada, M. (2022). Multiple myeloma management: What comes after lenalidomide-based therapy?. Canadian Hematology Today. https://doi.org/10.58931/cht.2022.1213

Vancouver

Louzada M. Multiple myeloma management: What comes after lenalidomide-based therapy?. Canadian Hematology Today. 2022. doi:10.58931/cht.2022.1213

BibTeX
@article{Louzada2022,
  author = {Louzada, Martha},
  title = {Multiple myeloma management: What comes after lenalidomide-based therapy?},
  journal = {Canadian Hematology Today},
  year = {2022},
  doi = {10.58931/cht.2022.1213}
}
Kostenlos starten →